<p>Omeros Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug), marking it as the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The company plans to launch YARTEMLEA in the U.S. market on January 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251226329520) on December 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

OMER

<p>Omeros Corporation announced FDA approval of YARTEMLEA® (narsoplimab-wuug), the first therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The U.S. launch is planned for January 2, 2026.</p>

FDA Approves Omeros' YARTEMLEA for TA-TMA